

ACIP Cholera Vaccine Working Group

Art Reingold, MD

October 21, 2015

Overview

- No cholera vaccine is currently licensed in the United States
- CVD 103-HgR is an oral cholera vaccine that is anticipated to be licensed in the United States in 2016
- ACIP cholera vaccine working group created to review evidence for use of oral cholera vaccine CVD 103-HgR in US adult travelers

Members

ACIP members

Art Reingold, chair

Laura E. Riley

ACIP liaison members

DoD: COL Margaret Yacovone

IDSA: Kathleen M. Neuzil

ACP: Sandra A. Fryhofer

NFID: Walt Orenstein

Other members

Myron M. Levine

Edward T. Ryan

Mary E. Wilson

Karen K. Wong, CDC co-lead

Barbara Mahon, CDC co-lead

Eric D. Mintz

Kashmira Date

Mark Gershman

John R. Su

Terms of reference

- Review data on safety, immunogenicity, and efficacy for CVD 103-HgR vaccine (PXVX0200)
- Propose ACIP recommendations for use of CVD 103-HgR in U.S. adult travelers and publish approved recommendations in *MMWR Recommendations and Reports*

Timeline

- PaxVax filed Biologics Licensing Application with FDA with request for priority review
- Anticipate completion of FDA review June 2016
- Plan to hold ACIP vote on recommendations for use of CVD 103-HgR after vaccine is licensed